Resitu's first product in development is an electrosurgical instrument intended for sampling of breast tissue during a breast biopsy procedure.
The instrument is a sterile, single-use device intended for use by radiologists and surgeons.
The device will extract larger tissue specimens than any other instrument, including core needle biopsy and vacuum assisted biopsy needles, extracting tissues of 1 x 3 cm in size, intact with preserved structure.
Preclinical studies are ongoing and clinical studies are planned for Q3 2022. The first instrument is expected to be CE marked and FDA cleared in 2023. Want to get more information?
Visit the contact page